Key Dates
PAR-20-117 - Maximizing Investigators’ Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional)
National Institute of General Medical Sciences (NIGMS)
The purpose of this Notice is to inform the biomedical research community that NIGMS is planning to issue a Funding Opportunity Announcement (FOA) to continue the Maximizing Investigators’ Research Award for Early Stage Investigators (MIRA-ESI) (R35) program. The FOA is intended for new applications from Early Stage Investigators.
This Notice is being provided to allow potential applicants sufficient time to develop responsive projects.The FOA is expected to be published in Spring 2023 with an expected first application due date in October 2023. This FOA will utilize the R35 activity code.
The NIGMS MIRA-ESI FOA is intended to provide support for the program of research in an ESI's laboratory that falls within the mission of NIGMS. ESIs are encouraged to submit an application early in their independent research careers and to move into research areas that are distinct from those of their postdoctoral mentors. Applicants who have not yet received independent research funding are encouraged to apply, as are those who have not had sufficient time and/or resources to generate independent senior author publications. Preliminary data are neither required nor expected, but if provided will be evaluated during the review process. Because the MIRA is intended to support a significant and ambitious program of research, the PD/PI is required to devote at least 51% of his/her total research effort to this award. MIRA-ESI applications are reviewed separately from established investigator MIRA applications.
Anticipated changes in this FOA reissuance include: (1) providing two application receipt dates per year - February and October; and (2) requiring a Plan for Enhancing Diverse Perspectives. Review criteria will be revised accordingly, and reviewers will be oriented to these new FOA goals.
TBD
TBD
$250,000
93.859
Applications are not being solicited at this time.
Please direct all inquiries to:
Sailaja Koduri, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Email: [email protected]